Stewart Ronald M, Park Pauline K, Hunt John P, McIntyre Robert C, McCarthy Janet, Zarzabal Lee Ann, Michalek Joel E
Department of Surgery, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229-3900, USA.
J Am Coll Surg. 2009 May;208(5):725-35; discussion 735-7. doi: 10.1016/j.jamcollsurg.2009.01.026. Epub 2009 Mar 31.
The ARDS Clinical Trials Network Fluid and Catheter Treatment Trial (FACTT) addressed fluid management and central monitoring of patients with acute respiratory distress syndrome/acute lung injury (ARDS/ALI). Because surgical patients may have been fundamentally different from the overall FACTT cohort, we set out to separately analyze the surgery patients in the trial.
We performed a posthoc, surgical subgroup analysis of 1,000 patients enrolled in the FACTT. Patients were randomized using a 2x2 factorial design comparing a conservative (CON) versus a liberal (LIB) strategy of fluid management and the use of a pulmonary artery catheter (PAC) or a central venous catheter (CVC). The primary end point was death at 60 days. Secondary end points included the number of ventilator-free days, ICU-free days, and dialysis-free days until hospital discharge up to day 90. We defined surgical patients as those admitted to a surgical ICU, burn ICU, or cardiac surgical ICU; trauma patients; or those with an APACHE III surgical admission type.
There were 244 surgical patients. Risk of death within 60 days of randomization did not vary with catheter or fluid management, and a corresponding lack of effect was evident with regard to dialysis-free days. Ventilator-free days were increased in the fluid-conservative group (LIB, 13+/-1 days; CON, 15+/-1 days; p=0.04) at 28 days. CVC patients had more ventilator-free days at 28 and 90 days (28 days: CVC, 16+/-1 days; PAC, 13+/-1 days; p=0.03; 90 days: CVC, 64+/-3 days; PAC, 57+/-4 days; p=0.03). CVC patients had more ICU-free days at 90 days (90 days: CVC, 63+/-3 days; PAC, 55+/-3 days; p=0.04).
The risk of death did not vary with fluid management or catheter. A conservative fluid-administration strategy and central venous catheter monitoring resulted in more ventilator-free and ICU-free days in surgical patients with acute lung injury, and conservative fluid administration did not result in more renal failure.
急性呼吸窘迫综合征临床试验网络液体与导管治疗试验(FACTT)探讨了急性呼吸窘迫综合征/急性肺损伤(ARDS/ALI)患者的液体管理及中心监测。由于外科患者可能与FACTT整体队列存在根本差异,我们着手对试验中的外科患者进行单独分析。
我们对FACTT纳入的1000例患者进行了事后外科亚组分析。患者采用2×2析因设计随机分组,比较液体管理的保守(CON)与宽松(LIB)策略以及肺动脉导管(PAC)或中心静脉导管(CVC)的使用情况。主要终点为60天死亡率。次要终点包括至90天出院时无呼吸机天数、无ICU天数和无透析天数。我们将外科患者定义为入住外科ICU、烧伤ICU或心脏外科ICU的患者、创伤患者或APACHE III外科入院类型的患者。
共有244例外科患者。随机分组后60天内的死亡风险并不随导管或液体管理而变化,且在无透析天数方面也明显缺乏相应影响。在第28天,液体保守组的无呼吸机天数增加(LIB组,13±1天;CON组,15±1天;p = 0.04)。在第28天和第90天,CVC患者的无呼吸机天数更多(第28天:CVC组,16±1天;PAC组,13±1天;p = 0.03;第90天:CVC组,64±3天;PAC组,57±4天;p = 0.03)。在第90天,CVC患者的无ICU天数更多(第90天:CVC组,63±3天;PAC组,55±3天;p = 0.04)。
死亡风险并不随液体管理或导管而变化。对于急性肺损伤的外科患者,保守的液体给药策略及中心静脉导管监测可带来更多的无呼吸机天数和无ICU天数,且保守的液体给药不会导致更多的肾衰竭。